Anzeige
Mehr »
Donnerstag, 09.10.2025 - Börsentäglich über 12.000 News
Kursrakete 2025: CiTech präsentiert sich u.a. mit DroneShield neben Palantir & Rheinmetall - welche News sind zu erwarten?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AP32 | ISIN: US74366E1029 | Ticker-Symbol: PGF
Tradegate
07.10.25 | 17:57
54,50 Euro
-3,54 % -2,00
1-Jahres-Chart
PROTAGONIST THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PROTAGONIST THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
56,0056,5008:27

Aktuelle News zur PROTAGONIST THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiBMO Capital reiterates Outperform rating on Protagonist Therapeutics stock2
DiProtagonist Therapeutics: Clear Street erhöht Kursziel nach Studiendaten deutlich auf 74 US-Dollar-
DiProtagonist Therapeutics stock price target raised to $74 at Clear Street1
DiProtagonist Therapeutics: Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill187Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose...
► Artikel lesen
26.09.Protagonist Therapeutics auf Rekordhoch: Aktie erreicht 66,7 US-Dollar4
17.09.Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews1
PROTAGONIST THERAPEUTICS Aktie jetzt für 0€ handeln
17.09.Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory2
17.09.This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday2
17.09.Protagonist Therapeutics: Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress198Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studiesIcotrokinra also showed sustained...
► Artikel lesen
15.09.Protagonist Therapeutics: Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025276NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in...
► Artikel lesen
12.09.This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday1
11.09.Protagonist Therapeutics: Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency301Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints....
► Artikel lesen
26.08.Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025289NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer...
► Artikel lesen
25.08.Protagonist Therapeutics: Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera335Breakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development programU.S. New Drug Application filing...
► Artikel lesen
07.08.What 4 Analyst Ratings Have To Say About Protagonist Therapeutics2
07.08.Protagonist Therapeutics stock price target raised to $69 by JMP1
06.08.Protagonist Therapeutics, Inc - 10-Q, Quarterly Report3
06.08.Protagonist Therapeutics: Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update310NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in JulyANTHEM Phase 2b trial data of icotrokinra...
► Artikel lesen
06.08.Protagonist Therapeutics, Inc - 8-K, Current Report4
21.07.Protagonist Therapeutics: Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis383Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptorFiling based on unprecedented data package that met all primary endpoints across four...
► Artikel lesen
Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1